Thermo Fisher Scientific Ataxin-1 Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 1:2,000–1:10,000

Immunoprecipitation (IP)

• Tested Dilution: 10 µg/mg lysate

Product Specifications

Product Specific Information

• Recommended shelf life: 1 year from date of receipt
• Predicted to react with Mouse and Rat (based on 100% sequence identity)

Target Information

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem, and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I–III.
ADCAI is genetically heterogeneous, with five genetic loci designated spinocerebellar ataxia (SCA) 1, 2, 3, 4, and 6, each assigned to different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII, often referred to as the "pure" cerebellar syndrome (SCA5), are most likely homogeneous disorders.
Several SCA genes contain CAG repeats in their coding regions, and ADCA is caused by expansion of these repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable and unstable, usually increasing in size in successive generations.
The function of the ataxins is not fully known. This locus has been mapped to chromosome 6, with diseased alleles containing 41–81 CAG repeats compared to 6–39 in normal alleles, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been identified for this gene.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.